Tag Archives | genetic sequencing

Biotech Hits New Highs for 2019:The Trends are Bullish…Update-3 at Sell-Off

4/11 ALERT: Need to check out reasons for biotech sell-off; could be proposed drug pricing bills and “affordability board.”  See STAT News . See 4/11 chart below for XBI. Choppy pattern returns at resistance with no breakthrough highs. Biopharma stocks broadly down on. “Red Screen Day”. 4/11/19 12:15p EDT. Update -2…Healthcare and biotech sector weak […]

Continue Reading 0

Biotech Green Screen: Sketchy Recovery is Underway…Update-3

Update-3…3/29 1:15p  EDT. Biotech stocks catching bids today after a choppy week of trading. We will recap our top small cap picks from the JPM Conference after the close: AMRN, GNMK and TDOC. BIIB up again to 237.  CELG up over 7% as prospects for BMY deal look good. ====== Update -2… 3/27. Choppy trendless […]

Continue Reading 0

Biotech Sell-Off: Momentum Eases on Profit Taking and Geopolitical Uncertainty…Update-2 Gene Therapy

Update-2…Biotech rally Friday and Gene Therapy stocks One clue to the stealth rally on Friday is this article in Barron’s published Saturday (? hmmm) Why Big Pharma is Diving into Gene Therapy If you cannot access this article and are not a subscriber go plunk down $5 as there is other good stuff on the […]

Continue Reading 0

Small Cap Biotechs Lead the Market in 2019 Up 20% YTD…GNMK, ONCE, XBI-Updates

Update: 1:40 EST 2/25… Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%. Another big deal as GE sells healthcare business to Danher (DHR) for $21.4B; GE up 8.26%, DHR up 8.38%. ========== M&A Drives Mid and Small Cap Biotechs Stocks Higher The Small Cap weighted XBI is up […]

Continue Reading 0

Emerging Growth Stocks: Long Ideas in Life Science for 2019…Updates-Risk On…FED on Hold and “Patient”

Update ….Jan 30 2:45p  EST …FED to be Patient and Policy Stance is Appropriate FED to “wait and see” before raising rates-stocks soar. FED-“US Economy in a good place” NASDAQ up 2%, DOW up 1.73%, S&P up 1.53% XLV up 1.27%, IBB flat, XBI up 1.72%. Large cap biopharmas trail broad rally: AMGN,BIIB in the […]

Continue Reading 0

Biotech Bull Market: ETFs and Life Science Mutual Funds 2018 YTD

Biotech Bull Market: Up 25.39% Over 2 Years With High Volatility  XBI Outperforms Up 12% YTD; FBT is Comparable, IBB lags. Three Funds did well in H1 2018 (7-9%). Biotech stocks peaked in July 2015 and reached a bottom on 10/31/16 gradually clawing their way back to a level about midway between the highs and lows […]

Continue Reading 0

Rayno BioBeat #4 2018: ASCO Biotech Momentum Continues with M&A Theme…Updates 6/29

Momentous  Biotech for June Update 6/28…A nice broad rally on Friday included the large cap biotechs with the IBB up 1.73% to $109.82. Even Celgene (CELG) found buyers up 3.6% flirting with the $80 level. The big winner was Vertex (VRTX) up 15.16% to the $170 level on news that a rival Company Galapagos (GLPG) […]

Continue Reading 0

Rayno Life Science Portfolio Flash Update: Roche and FMI Merger; Update with XBI breakout

Rayno Life Science Portfolio FMI: Personalized Medicine for Oncology We are on vacation this week but need to update you on Roche (RHHBY) complete buyout of Foundation Medicine (FMI) one of our top picks in personalized medicine for oncology. FMI is up 28% to $136.50 in the pre-market. We added FMI to our top picks on […]

Continue Reading 0

Biotech Mid-Caps: The Momentum Trade is Back FMI, LOXO,XBI etc

Biotech Mid-Caps- Momentum Trade is Back ASCO Abstracts Provide Clinical Updates But as of 2 P EDT Stocks Are Being Hit By Profit Taking XBI at $92.39 Biotech mid-caps had a good week ending 5/18 as tracked by the top performing XBI which was up 2%  and over 10% in 2018 YTD. The large cap […]

Continue Reading 0

2018 J.P.Morgan Healthcare Conference #4 Notes from Panel: Key Trends in Diagnostics and Lifesciences

Key Trends in Diagnostics and Lifesciences: Promise, Reality Reimbursement Panel Moderator: Ken Bahk, Three Lake Partners. Panelists- Nathan Ledeboer, Medical College of Wisconsin,Victoria Pratt, Indiana University School of Medicine, Nick Papadopolous, Johns Hopkins School of Medicine. Here are some takeaways from the session that covers novel tests, clinical diagnostic reimbursement and CPT codes(no slides were […]

Continue Reading 0